Prevention of respiratory syncytial virus infection in infants: Palivizumab is effective but too expensive, and vaccines are unavailable as yet

AUTOR(ES)

Handforth, Jenny

FONTE

BMJ Publishing Group Ltd.

Documentos Relacionados

• Prevention of respiratory syncytial virus infection
• Genotypes and clinical data of respiratory syncytial virus and metapneumovirus in brazilian infants: a new perspective
• Prevention of coronary heart disease: Is a cure too expensive?
• Respiratory syncytial virus: pervasive yet evasive
• Respiratory Syncytial Virus Vaccines